Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.

To determine independent correlates of pCR, variables with a trend toward significance on univariate testing ( p <0.20) were entered into a forward, stepwise multivariable logistic regression model ( p <0.05 for entry, p <0.10 for exit).

also in 3,729 other papers

Although pCR patients demonstrated a trend toward presentation at lower (i.e., stage II) clinical stage (68.8 % vs 41.7 %, p = 0.12) and less frequent need for mastectomy (50.0 % vs 79.2 %, p = 0.09), these comparisons did not reach statistical significance (Table 2 ).

also in 111,027 other papers